Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ARAY 
Accuray Incorporated (ARAY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: ARAY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.88
1 Year Target Price $3.88
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.23% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 93.54M USD | Price to earnings Ratio - | 1Y Target Price 3.88 |
Price to earnings Ratio - | 1Y Target Price 3.88 | ||
Volume (30-day avg) 4 | Beta 1.07 | 52 Weeks Range 0.81 - 2.95 | Updated Date 12/27/2025 |
52 Weeks Range 0.81 - 2.95 | Updated Date 12/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -4.28% | Operating Margin (TTM) 3.73% |
Management Effectiveness
Return on Assets (TTM) 0.2% | Return on Equity (TTM) -36.07% |
Valuation
Trailing PE - | Forward PE 94.34 | Enterprise Value 209309436 | Price to Sales(TTM) 0.21 |
Enterprise Value 209309436 | Price to Sales(TTM) 0.21 | ||
Enterprise Value to Revenue 0.46 | Enterprise Value to EBITDA 27.29 | Shares Outstanding 113341132 | Shares Floating 107807818 |
Shares Outstanding 113341132 | Shares Floating 107807818 | ||
Percent Insiders 4.24 | Percent Institutions 69.81 |
Upturn AI SWOT
Accuray Incorporated
Company Overview
History and Background
Accuray Incorporated was founded in 1990. It pioneered frameless radiosurgery and has been a significant player in the development of advanced radiation oncology systems. Key milestones include the introduction of the CyberKnife system, which revolutionized the treatment of tumors with pinpoint accuracy, and the subsequent integration of the TomoTherapy system, offering advanced helical IMRT capabilities. Accuray has evolved from a niche technology provider to a broader solutions company in the oncology space.
Core Business Areas
- Radiation Oncology Systems: Accuray designs, manufactures, and sells advanced radiation oncology systems used to treat cancer. These systems deliver precisely targeted radiation doses to cancerous tumors while minimizing damage to surrounding healthy tissue.
- Software and Services: Beyond hardware, Accuray offers a suite of software solutions for treatment planning and delivery, as well as comprehensive service, maintenance, and training programs for its systems.
Leadership and Structure
Accuray Incorporated is led by a management team with expertise in medical technology and oncology. The company operates with a global sales and service network to support its installed base of systems. Key leadership roles include CEO, CFO, and heads of R&D, sales, and marketing.
Top Products and Market Share
Key Offerings
- CyberKnife System: A robotic, image-guided radiosurgery platform that delivers highly precise radiation treatments for a wide range of tumors throughout the body. It is known for its ability to track tumor movement in real-time. Competitors include Varian Medical Systems (now Siemens Healthineers), Elekta, and RaySearch Laboratories.
- TomoTherapy System: A helical IMRT (Intensity-Modulated Radiation Therapy) platform that integrates CT imaging with radiation delivery, allowing for precise and efficient cancer treatment. Competitors include Varian Medical Systems (now Siemens Healthineers), Elekta, and other providers of LINAC-based IMRT systems.
Market Dynamics
Industry Overview
The radiation oncology market is driven by an aging global population, increasing cancer incidence rates, and advancements in treatment technologies aimed at improving efficacy and reducing side effects. Key trends include the adoption of precision medicine, AI-driven treatment planning, and the demand for integrated oncology solutions.
Positioning
Accuray is positioned as a leader in advanced radiation therapy, particularly in the niche of highly precise and image-guided treatments. Its strengths lie in its innovative technologies like the CyberKnife system and its focus on simplifying complex cancer treatments for clinicians.
Total Addressable Market (TAM)
The global radiation therapy market is estimated to be in the tens of billions of dollars and is projected to grow steadily. Accuray addresses a significant portion of this market with its specialized systems, targeting centers seeking advanced treatment capabilities.
Upturn SWOT Analysis
Strengths
- Proprietary and advanced technology (e.g., CyberKnife, TomoTherapy)
- Strong reputation for precision and image-guidance
- Global installed base and service network
- Focus on simplifying complex treatments
Weaknesses
- Higher price point for some systems can be a barrier
- Reliance on capital equipment sales, which can be cyclical
- Competition from larger, more diversified medical device companies
Opportunities
- Expansion into emerging markets
- Development of next-generation technologies and AI integration
- Growth in demand for non-invasive cancer treatments
- Potential for strategic partnerships and acquisitions
Threats
- Intense competition and pricing pressures
- Regulatory hurdles and changes in reimbursement policies
- Economic downturns impacting healthcare capital spending
- Rapid technological advancements by competitors
Competitors and Market Share
Key Competitors
- Varian Medical Systems (now part of Siemens Healthineers)
- Elekta AB
- RaySearch Laboratories AB
Competitive Landscape
Accuray's competitive advantage lies in its specialized technologies like CyberKnife for highly precise treatments. However, it faces intense competition from larger players with broader product portfolios and established market dominance. Pricing, innovation, and service offerings are key differentiators.
Growth Trajectory and Initiatives
Historical Growth: Accuray has experienced periods of growth driven by product innovation and market adoption, alongside challenges related to market cycles and competition. Detailed historical revenue and EPS trends are available in financial reports.
Future Projections: Future growth projections for Accuray are influenced by market trends in radiation oncology, new product development, and global healthcare spending. Analyst reports typically provide forward-looking estimates.
Recent Initiatives: Recent initiatives likely focus on expanding the product portfolio, enhancing software capabilities, improving system efficiency, and strengthening global market presence through sales and distribution enhancements.
Summary
Accuray Incorporated is a specialized player in the radiation oncology market, known for its innovative and precise treatment systems like CyberKnife. While it possesses strong technological advantages and a global presence, it faces significant competition and market cyclicality. The company needs to focus on continuous innovation, market expansion, and efficient operations to sustain and grow its market position.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations websites
- Financial News and Analysis Platforms
- Industry Market Research Reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Market share data is an estimation and may vary across different market segments and reporting periods. Financial performance figures should be verified with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Accuray Incorporated
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2007-02-08 | President, CEO & Director Mr. Stephen R. LaNeve MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 990 | Website https://www.accuray.com |
Full time employees 990 | Website https://www.accuray.com | ||
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.